Hamostaseologie最新文献_第2页

Thrombosis at Unusual Sites: Focus on Myeloproliferative Neoplasms and Paroxysmal Nocturnal Hemoglobinuria. 不寻常部位的血栓形成：集中于骨髓增生性肿瘤和阵发性夜间血红蛋白尿。

IF 2.7 4区医学

Hamostaseologie Pub Date : 2025-04-01 Epub Date: 2025-02-03 DOI: 10.1055/a-2482-3997

Steffen Koschmieder, Jens Panse

{"title":"Thrombosis at Unusual Sites: Focus on Myeloproliferative Neoplasms and Paroxysmal Nocturnal Hemoglobinuria.","authors":"Steffen Koschmieder, Jens Panse","doi":"10.1055/a-2482-3997","DOIUrl":"10.1055/a-2482-3997","url":null,"abstract":"Patients with thrombosis at an unusual site will need to be explored for rare causes of thrombosis. Two of these rare causes include myeloproliferative neoplasms (MPNs) and paroxysmal nocturnal hemoglobinuria (PNH). It is important not to overlook these causes, since they require specific management, in addition to antithrombotic treatment (anticoagulants, antiplatelet agents). Unusual sites of venous thrombosis include upper extremity veins, splanchnic veins, cerebral veins, and retinal veins, and unusual sites of arterial thrombosis include renal, adrenal, splenic and mesenteric arteries, and intracardiac and aortal locations. Suspicion for MPN and PNH should be raised if there are concomitant abnormalities, such as elevated or decreased blood cell counts or splenomegaly. Diagnosis of MPN and PNH should include JAK2V617F mutational screening as well as flow cytometric assessment of GPI-anchored proteins in the peripheral blood, respectively. Specific treatments for MPN may include phlebotomy or cytoreductive drugs such as hydroxyurea, anagrelide, pegylated interferon-alpha, or Janus kinase inhibitors. Drugs used for PNH treatment include terminal complement inhibitors, such as eculizumab and ravulizumab, as well as proximally acting inhibitors such as pegcetacoplan or iptacopan. Patients with MPN and PNH are at high risk for thrombosis during their entire lifetime and should thus be followed by specialists experienced in the care of these diseases.","PeriodicalId":55074,"journal":{"name":"Hamostaseologie","volume":" ","pages":"166-174"},"PeriodicalIF":2.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143124200","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Die Gesellschaft für Thrombose- und Hämostaseforschung e.V. Informiert. 血栓和止血研究协会。

IF 2.7 4区医学

Hamostaseologie Pub Date : 2025-04-01 Epub Date: 2025-05-04 DOI: 10.1055/a-2534-2806

引用次数: 0

Echtzeit-Bildgebung der durch Blutplättchen induzierten Blutgerinnselbildung und -auflösung zeigt unterschiedliche Auswirkungen von Antikoagulantien. 对血小板诱导的凝血形成和溶解的实时成像显示了抗凝药物的不同作用。

IF 2.7 4区医学

Hamostaseologie Pub Date : 2025-04-01 Epub Date: 2025-05-07 DOI: 10.1055/s-0045-1809295

引用次数: 0

Checkpoint Inhibitors, CAR T Cells, and the Hemostatic System: What Do We Know So Far? 检查点抑制剂，CAR - T细胞和止血系统：到目前为止我们知道什么？

IF 2.7 4区医学

Hamostaseologie Pub Date : 2025-04-01 Epub Date: 2025-05-07 DOI: 10.1055/a-2528-5071

Christina C Rolling, Samuel Lewirt, Antonia Beitzen-Heineke, Lennart Beckmann, Carsten Bokemeyer, Winfried Alsdorf, Minna Voigtlaender, Florian Langer

{"title":"Checkpoint Inhibitors, CAR T Cells, and the Hemostatic System: What Do We Know So Far?","authors":"Christina C Rolling, Samuel Lewirt, Antonia Beitzen-Heineke, Lennart Beckmann, Carsten Bokemeyer, Winfried Alsdorf, Minna Voigtlaender, Florian Langer","doi":"10.1055/a-2528-5071","DOIUrl":"https://doi.org/10.1055/a-2528-5071","url":null,"abstract":"Immune checkpoint inhibitors (ICIs) and chimeric antigen receptor (CAR) T cells are novel therapeutic strategies that enhance anticancer immunity by activating or engineering cancer-targeting T cells. The resulting hyperinflammation carries several side effects, ranging from autoimmune-like symptoms to cytokine release syndrome (CRS), with potentially severe consequences. Recent findings indicate that ICIs increase the risk of venous and arterial thromboembolic adverse events. Patients with prior VTE might be at higher risk of developing new events under ICI while other risk factors vary across studies. So far, data on CAR T-linked coagulopathies are limited. Hypofibrinogenemia in the presence of CRS is the most commonly observed dysregulation of hemostatic parameters. A rare but particularly severe adverse event is the development of disseminated intravascular coagulation activation, which can occur in the setting of CRS and may be linked to immune effector cell-associated hemophagocytic lymphohistiocytosis. While the increasing number of studies on thromboembolic complications and coagulation alterations under ICIs and CAR T therapies are concerning, these results might be influenced by the retrospective study design and the heterogeneous patient populations. Importantly, numerous promising new T cell-based immunotherapies are currently under investigation for various cancers and are expected to become very prominent therapy options in the near future. Therefore, coagulopathies and thrombosis under T cell-directed immuno- and anti-cancer therapies is important. Our review provides an overview of the current understanding of ICI- and CAR T-associated thromboembolism. We discuss pathogenic mechanisms of inflammation-associated coagulation activation and explore potential biomarkers for VTE.","PeriodicalId":55074,"journal":{"name":"Hamostaseologie","volume":"45 2","pages":"175-187"},"PeriodicalIF":2.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144058309","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Bleeding Risk in Patients with Cancer. 癌症患者的出血风险。

IF 2.7 4区医学

Hamostaseologie Pub Date : 2025-04-01 Epub Date: 2024-09-03 DOI: 10.1055/a-2347-6507

Cornelia Englisch, Nikola Vladic, Cihan Ay

{"title":"Bleeding Risk in Patients with Cancer.","authors":"Cornelia Englisch, Nikola Vladic, Cihan Ay","doi":"10.1055/a-2347-6507","DOIUrl":"10.1055/a-2347-6507","url":null,"abstract":"The hemostatic system and cancer display a tight interconnection, and hemostatic imbalance frequently occurs in patients with cancer. While extensive knowledge about thrombotic risk has been generated, less is known about bleeding risk and associated risk factors. However, bleeding risk is of high significance as patients with cancer frequently receive therapeutic anticoagulation for various indications and/or are candidates for primary thromboprophylaxis. The risk of bleeding in patients with cancer is variable and difficult to assess in clinical practice. Certain clinical settings such as hospitalization, specific underlying risk factors (e.g., tumor type), and medications (e.g., anticoagulation) can contribute to the individual bleeding risk of a patient with cancer. In addition, some dynamic factors such as platelet count or kidney function have an impact. Particularly, data on baseline risk of bleeding are lacking to allow for risk assessment in cancer patients without anticoagulation. In contrast, risk assessment models for the prediction of bleeding events in cancer patients receiving anticoagulation have been developed; however, these have yet to be validated. The recognition of the importance of bleeding risk in cancer patients is growing, leading to an increasing number of studies investigating and reporting bleeding complications. As study designs and reporting of bleeding events vary, it is challenging to offer a clear synthesis of evidence. In this narrative review, we provide an overview of currently available data about incidence, risk factors, and clinical impact of bleeding events in patients with cancer, and critically review risk assessment models for bleeding in cancer patients during anticoagulant therapy.","PeriodicalId":55074,"journal":{"name":"Hamostaseologie","volume":" ","pages":"188-203"},"PeriodicalIF":2.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142127420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Primary Prevention of Cancer-Associated Thrombosis: Current Perspectives. 癌症相关血栓的初级预防：当前视角。

IF 2.7 4区医学

Hamostaseologie Pub Date : 2025-04-01 Epub Date: 2024-10-10 DOI: 10.1055/a-2374-3425

Christina Hart, Nick van Es, Minna Voigtlaender

{"title":"Primary Prevention of Cancer-Associated Thrombosis: Current Perspectives.","authors":"Christina Hart, Nick van Es, Minna Voigtlaender","doi":"10.1055/a-2374-3425","DOIUrl":"10.1055/a-2374-3425","url":null,"abstract":"Over the past two decades, the incidence of cancer-associated thrombosis (CAT) has increased. It is nowadays a common and often serious complication among patients with cancer. Although medical thromboprophylaxis is recommended for most surgical and nonsurgical cancer patients, it has been infrequently used in ambulatory patients with cancer because of the burden of treatment and concerns about bleeding. However, various risk assessment scores are now available and randomized placebo-controlled trials have established the efficacy of low-molecular-weight heparin or the direct oral Xa inhibitors rivaroxaban and apixaban in ambulatory patients with cancer at high risk of venous thromboembolism (VTE). This review provides an overview of (1) primary thromboprophylaxis in the setting of hospitalized surgical and medical patients, (2) extended thromboprophylaxis after hospital discharge, (3) performance of risk assessment tools for CAT, and (4) primary thromboprophylaxis in ambulatory patients with cancer. The aim is to provide support to physicians in identifying ambulatory patients with cancer at high VTE risk who benefit most from medical thromboprophylaxis according to current recommendations from international guidelines.","PeriodicalId":55074,"journal":{"name":"Hamostaseologie","volume":" ","pages":"127-138"},"PeriodicalIF":2.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142402056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Treatment of Cancer-Associated Thrombosis: An Update. 癌症相关血栓的治疗：最新进展。

IF 2.7 4区医学

Hamostaseologie Pub Date : 2025-04-01 Epub Date: 2024-11-05 DOI: 10.1055/a-2420-7684

Minna Voigtlaender, Christina Rolling, Christina Hart

{"title":"Treatment of Cancer-Associated Thrombosis: An Update.","authors":"Minna Voigtlaender, Christina Rolling, Christina Hart","doi":"10.1055/a-2420-7684","DOIUrl":"10.1055/a-2420-7684","url":null,"abstract":"Patients with cancer are at increased risk of venous thromboembolism (VTE). Treatment of VTE remains challenging due to a significant risk of both VTE recurrence and bleeding compared with patients without underlying malignancy. Moreover, patients with cancer often present with several comorbidities such as tumor- or treatment-induced bone marrow failure, renal impairment, and extensive concomitant anticancer or supportive medication, resulting in potential drug-drug interactions. Further challenging circumstances include gastrointestinal (GI) disorders, in the context of a GI intraluminal tumor itself, GI surgery, or systemic therapy-induced GI toxicity. However, treatment options and study data in the management of cancer-associated thrombosis (CAT) have expanded over the last few years. As a result, it is becoming increasingly important to assess the patient's individual risk of bleeding and its comorbidities, and the patient's personal preferences. Prospectively, further therapeutic strategies such as factor XIa inhibitors are under clinical investigation. The aim of our narrative review is to summarize the current literature on therapy options for CAT, including common treatment situations encountered in the management of patients with cancer.","PeriodicalId":55074,"journal":{"name":"Hamostaseologie","volume":" ","pages":"139-149"},"PeriodicalIF":2.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142584917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Ausgewählte Beiträge der BDDH-Veranstaltung im Rahmen der 69. Jahrestagung der Gesellschaft für Thrombose- und Hämostaseforschung (GTH) am 18.02.2025 in Lausanne. 在第69届BDH会议上选定的贡献。血栓和止血研究学会（GTH）年会于2025年2月18日在洛桑举行。

IF 2.7 4区医学

Hamostaseologie Pub Date : 2025-04-01 Epub Date: 2025-05-07 DOI: 10.1055/a-2447-6517

Christoph Sucker, Jürgen Koscielny, Günther Kappert

引用次数: 0

Update on Cancer-Associated Venous Thromboembolism in Children. 儿童癌症相关静脉血栓栓塞的最新进展。

IF 2.7 4区医学

Hamostaseologie Pub Date : 2025-04-01 Epub Date: 2024-12-10 DOI: 10.1055/a-2407-7914

Rahel Kasteler, Manuela Albisetti, Alessandra Bosch

引用次数: 0

Challenging Situations in the Treatment of Cancer-Associated Thrombosis. 癌症相关血栓治疗面临的挑战